Editorial: Megakaryocytes As Regulators of Tumor Microenvironments

Overview

Journal Front Oncol

Specialty Oncology

Date 2022 Dec 12

PMID 36505825

Authors

Anna Rita Migliaccio

Alessandra Balduini

Huichun Zhan

Affiliations

Soon will be listed here.

Citing Articles

Revisiting Circulating Extracellular Matrix Fragments as Disease Markers in Myelofibrosis and Related Neoplasms.

Hasselbalch H, Junker P, Skov V, Kjaer L, Knudsen T, Larsen M Cancers (Basel). 2023; 15(17).

PMID: 37686599 PMC: 10486581. DOI: 10.3390/cancers15174323.

References

Tefferi A . Pathogenesis of myelofibrosis with myeloid metaplasia. J Clin Oncol. 2005; 23(33):8520-30. DOI: 10.1200/JCO.2004.00.9316. View

Yeung A, Villacorta-Martin C, Hon S, Rock J, Murphy G . Lung megakaryocytes display distinct transcriptional and phenotypic properties. Blood Adv. 2020; 4(24):6204-6217. PMC: 7757004. DOI: 10.1182/bloodadvances.2020002843. View

Tefferi A, Vaidya R, Caramazza D, Finke C, Lasho T, Pardanani A . Circulating interleukin (IL)-8, IL-2R, IL-12, and IL-15 levels are independently prognostic in primary myelofibrosis: a comprehensive cytokine profiling study. J Clin Oncol. 2011; 29(10):1356-63. DOI: 10.1200/JCO.2010.32.9490. View

Bruns I, Lucas D, Pinho S, Ahmed J, Lambert M, Kunisaki Y . Megakaryocytes regulate hematopoietic stem cell quiescence through CXCL4 secretion. Nat Med. 2014; 20(11):1315-20. PMC: 4258871. DOI: 10.1038/nm.3707. View

Emadi S, Clay D, Desterke C, Guerton B, Maquarre E, Charpentier A . IL-8 and its CXCR1 and CXCR2 receptors participate in the control of megakaryocytic proliferation, differentiation, and ploidy in myeloid metaplasia with myelofibrosis. Blood. 2004; 105(2):464-73. DOI: 10.1182/blood-2003-12-4415. View

Verstovsek S, Mesa R, Gotlib J, Gupta V, Dipersio J, Catalano J . Long-term treatment with ruxolitinib for patients with myelofibrosis: 5-year update from the randomized, double-blind, placebo-controlled, phase 3 COMFORT-I trial. J Hematol Oncol. 2017; 10(1):55. PMC: 5322633. DOI: 10.1186/s13045-017-0417-z. View

Kaushansky K . Lineage-specific hematopoietic growth factors. N Engl J Med. 2006; 354(19):2034-45. DOI: 10.1056/NEJMra052706. View

Malara A, Currao M, Gruppi C, Celesti G, Viarengo G, Buracchi C . Megakaryocytes contribute to the bone marrow-matrix environment by expressing fibronectin, type IV collagen, and laminin. Stem Cells. 2013; 32(4):926-37. PMC: 4096110. DOI: 10.1002/stem.1626. View

Zhan H, Ma Y, Lin C, Kaushansky K . JAK2-mutant megakaryocytes contribute to hematopoietic stem/progenitor cell expansion in a model of murine myeloproliferation. Leukemia. 2016; 30(12):2332-2341. PMC: 5158308. DOI: 10.1038/leu.2016.114. View

10.

Karagianni A, Ravid K . Myeloproliferative disorders and their effects on bone homeostasis: the role of megakaryocytes. Blood. 2021; 139(21):3127-3137. PMC: 9136883. DOI: 10.1182/blood.2021011480. View

11.

Zhao M, Perry J, Marshall H, Venkatraman A, Qian P, He X . Megakaryocytes maintain homeostatic quiescence and promote post-injury regeneration of hematopoietic stem cells. Nat Med. 2014; 20(11):1321-6. DOI: 10.1038/nm.3706. View

12.

Witkowski M, Dolgalev I, Evensen N, Ma C, Chambers T, Roberts K . Extensive Remodeling of the Immune Microenvironment in B Cell Acute Lymphoblastic Leukemia. Cancer Cell. 2020; 37(6):867-882.e12. PMC: 7341535. DOI: 10.1016/j.ccell.2020.04.015. View

13.

Wang J, Xie J, Wang D, Han X, Chen M, Shi G . CXCR4 megakaryocytes regulate host-defense immunity against bacterial pathogens. Elife. 2022; 11. PMC: 9374440. DOI: 10.7554/eLife.78662. View

14.

Abbonante V, Di Buduo C, Gruppi C, Malara A, Gianelli U, Celesti G . Thrombopoietin/TGF-β1 Loop Regulates Megakaryocyte Extracellular Matrix Component Synthesis. Stem Cells. 2016; 34(4):1123-33. DOI: 10.1002/stem.2285. View

15.

Wang H, He J, Xu C, Chen X, Yang H, Shi S . Decoding Human Megakaryocyte Development. Cell Stem Cell. 2020; 28(3):535-549.e8. DOI: 10.1016/j.stem.2020.11.006. View

16.

Ciurea S, Merchant D, Mahmud N, Ishii T, Zhao Y, Hu W . Pivotal contributions of megakaryocytes to the biology of idiopathic myelofibrosis. Blood. 2007; 110(3):986-93. PMC: 1924766. DOI: 10.1182/blood-2006-12-064626. View

17.

Hao Q, Vadgama J, Wang P . CCL2/CCR2 signaling in cancer pathogenesis. Cell Commun Signal. 2020; 18(1):82. PMC: 7257158. DOI: 10.1186/s12964-020-00589-8. View

18.

Barbui T, Tefferi A, Vannucchi A, Passamonti F, Silver R, Hoffman R . Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet. Leukemia. 2018; 32(5):1057-1069. PMC: 5986069. DOI: 10.1038/s41375-018-0077-1. View

19.

Eran Z, Zingariello M, Bochicchio M, Bardelli C, Migliaccio A . Novel strategies for the treatment of myelofibrosis driven by recent advances in understanding the role of the microenvironment in its etiology. F1000Res. 2019; 8. PMC: 6758840. DOI: 10.12688/f1000research.18581.1. View

20.

Pariser D, Hilt Z, Ture S, Blick-Nitko S, Looney M, Cleary S . Lung megakaryocytes are immune modulatory cells. J Clin Invest. 2020; 131(1). PMC: 7773372. DOI: 10.1172/JCI137377. View